ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Adaptimmune Therapeutics PLC

Financials through Q2 FY2025, quarter ended Jun 30, 2025Last filing: 10-Q on Aug 13, 2025

$0.04+0.00 (+9.38%)

Close on Oct 19, 2026

Market cap: $55.46M
P/E (TTM): –
Dividend yield: –

Adaptimmune Therapeutics PLC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2015 2015-06-30	FY 2014 2014-06-30
Revenue	178	60	27	6.15	3.96	1.12	60	38	9.87	0.83
Cost of Revenue	0.07	–	–	–	–	–	–	–	–	–
Gross Profit	178	–	–	–	–	–	–	–	–	–
Research & Development	149	127	128	111	92	98	98	87	24	9.58
Selling, General & Admin	87	74	63	–	–	–	–	–	–	–
General & Administrative	–	74	63	57	46	43	44	31	10	2.77
Total Costs & Expenses	247	200	191	168	137	141	142	118	35	12
Operating Income	-69	-140	-164	-162	-133	-140	-82	-81	-25	-12
Interest Expense	3.35	–	–	–	–	–	–	–	–	–
Interest & Investment Income	–	–	–	–	–	2.77	2.85	2.23	0.50	–
Other Non-Operating Income	-1.73	-0.81	-0.54	3.85	1.16	0.08	-16	8.74	2.32	-0.01
Merger & Restructuring Charges	1.54	1.62	2.29	–	–	–	–	–	–	–
Asset Impairment Charges	0	0	0	–	–	–	–	–	–	–
Pretax Income	-67	-113	-163	-157	-130	-137	-95	-70	-22	-12
Income Tax Expense	3.58	1.34	2.50	0.79	0.16	0.24	0.50	0.45	0.24	0.08
Net Income incl. Noncontrolling Interests	-71	-114	-165	-158	-130	-137	-96	-70	-22	–
Net Income	-71	-114	-165	-158	-130	-137	-96	-70	-22	-12
Net Income to Common	-71	-114	-165	-158	-130	-137	-96	-70	-37	-12
EPS (Basic)(per share)	-0.05	-0.09	-0.17	-0.17	-0.15	-0.22	-0.16	-0.13	-0.17	-0.08
EPS (Diluted)(per share)	-0.05	-0.09	-0.17	-0.17	-0.15	-0.22	-0.16	-0.13	-0.17	-0.08
Shares Outstanding (Basic, Weighted)(shares)	1,514	1,206	967	935	855	630	584	528	215	148
Shares Outstanding (Diluted, Weighted)(shares)	1,514	1,206	967	935	855	630	584	528	215	148

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2025

Profitability, TTM

Gross margin: 273.4%
Operating margin: -252.3%
Net margin: -260.8%
Return on equity, FY2024: -275.7%

Financial strength

Current ratio: 1.52
Debt to equity: -0.36
Debt to assets: 19.7%
Cash to current liabilities: 50.6%

Valuation

P/E ratio: –
Price to sales: 0.85
Price to book: –
Dividend yield: –